(MedPage Today) — The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory condition in the U.S., drugmaker Celltrion announced Monday.
The anti-immunoglobulin E (IgE) antibody…
Source link : https://www.medpagetoday.com/allergyimmunology/asthma/114576
Author :
Publish date : 2025-03-10 19:18:00
Copyright for syndicated content belongs to the linked Source.
